GENOMICALLY-GUIDED TREATMENT TRIAL IN BRAIN METASTASES

Open

Phase

Abbreviated Title

GENOMICALLY-GUIDED TREATMENT IN BRAIN METASTASES

Status Notes

Step 0 & Step 1 Activation Effective 8/15/19; SWOG Activation Effective 9/1/19

Effective Tuesday, January 9, 2024, new patient registration (Step 1) to the entrectinib (NTRK/ROS1) cohort is closed.

Effective Friday, April 4, 2025, new patient registration (Step 1) to the MRTX849 (adagrasib) (KRAS G12C) cohort will be closed. The manufacturer of the investigational agent MRTX849 (adagrasib) will soon discontinue drug supply to new patients on Alliance A071701.

Activated

09/01/2019

Participants

ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE

Research committees

Early Therapeutics & Rare Cancers

Eligibility Criteria Expand/Collapse

Eligibility criteria are accessible from the protocol abstract page on the CTSU website (http://www.ctsu.org ).

Other Clinical Trials

SWOG Clinical Trial Number

CTSU/AOST2032

AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma

Research Committee(s)

Early Therapeutics & Rare Cancers

Activated

02/17/2023

Open

SWOG Clinical Trial Number

CTSU/AOST2031

AOST2031: A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma

Research Committee(s)

Early Therapeutics & Rare Cancers

Activated

02/15/2022

Open

SWOG Clinical Trial Number

S2012

Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)

Research Committee(s)

Early Therapeutics & Rare Cancers

Activated

12/02/2021

Accrual

69%

Open

Phase